表紙
市場調査レポート

Dupilumab(アトピー性皮膚炎):予測と市場分析

Dupilumab (Atopic Dermatitis) - Forecast and Market Analysis to 2022

発行 GlobalData 商品コード 292830
出版日 ページ情報 英文 68 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.55円で換算しております。
Back to Top
Dupilumab(アトピー性皮膚炎):予測と市場分析 Dupilumab (Atopic Dermatitis) - Forecast and Market Analysis to 2022
出版日: 2013年11月30日 ページ情報: 英文 68 Pages
概要

当レポートでは、SanofiとRegeneronが共同開発中の、IL-4Rαに対する完全ヒトモノクローナル抗体(mAb)Dupilumabについて調査分析し、アトピー性皮膚炎の概要と治療ガイドライン、競合情勢、製品情報、主要国の売上予測、売上情報などを提供して、概略以下の構成でお届けいたします。

第1章 目次

第2章 イントロダクション

第3章 疾病の概要

  • 病因・病態生理
    • 病因
    • 病態生理
  • 症状

第4章 疾病の管理

  • 診断
  • 治療の概要

第5章 競合評価

  • 概要
  • 戦略的競合企業の評価

第6章 機会とアンメットニーズ

  • 概要
  • アンメットニーズ
  • アンメットニーズのギャップ分析
  • 機会

第7章 パイプライン評価

  • 概要
  • 臨床開発中の有望薬

第8章 Dupilumab(SAR231893/REGN668)

  • 概要
  • 効能
  • 安全性
  • 投与・処方
  • 潜在的な臨床的位置付け
  • 潜在的な商業的位置付け
  • 価格と償還
  • SWOT分析
  • 予測

第9章 付録

図表

目次
Product Code: GDHC296DFR

Although the past decade has seen the atopic dermatitis market remain relatively unchanged and a saturated, highly genericized arena, the coming decade could see the launch of the first biologic, which will set a precedent and pave the way for others to follow suit.

Sanofi and Regeneron are co-developing dupilumab, a novel, fully human monoclonal antibody (mAb) directed against IL-4R a, as a potential treatment for atopic dermatitis and asthma. Atopic dermatitis is often the first manifestation of atopy (the genetic disposition to develop an allergic reaction) in many patients who later develop other atopic disorders such as allergic rhinitis, asthma, or both, in a process referred to as the atopic march or allergic march.

Scope

  • Overview of Atopic Dermatitis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Dupilumab including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Dupilumab for the top nine countries from 2012 to 2022.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, India and China.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Atopic Dermatitis
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Dupilumab performance
  • Obtain sales forecast for Dupilumab from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, the UK, Japan, India and China)

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Symptoms

4. Disease Management

  • 4.1. Diagnosis
  • 4.2. Treatment Overview

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment

6. Opportunity and Unmet Need

  • 6.1. Overview
  • 6.2. Unmet Needs
    • 6.2.1. A Systemic Drug for Severe Recalcitrant Patients
    • 6.2.2. Tests that Stratify Patients and Allow for a Tailored Treatment Approach
    • 6.2.3. A Drug that Effectively Controls Patients' Pruritus
    • 6.2.4. Further Research into the Pathophysiology of Atopic Dermatitis
    • 6.2.5. A Drug that Induces Disease Remission
    • 6.2.6. Improved Quality of Life for Both Patients and their Carers
  • 6.3. Unmet Needs Gap Analysis
  • 6.4. Opportunities
    • 6.4.1. Increase Treatment Armamentarium for Severe Recalcitrant Patients
    • 6.4.2. Predictive Tests for Patient Stratification
    • 6.4.3. More Therapeutic Options that Address Patients' Pruritus

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Promising Drugs in Clinical Development

8. Dupilumab (SAR231893/ REGN668)

  • 8.1. Overview
  • 8.2. Efficacy
  • 8.3. Safety
  • 8.4. Dosing and Formulation
  • 8.5. Potential Clinical Positioning
  • 8.6. Potential Commercial Positioning
  • 8.7. Pricing and Reimbursement

8.8. SWOT Analysis

  • 8.9. Forecast

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Diagnosed Atopic Dermatitis Patients
    • 9.4.2. Percent Drug-treated Patients
    • 9.4.3. General Pricing Assumptions
    • 9.4.4. Generic Erosion
    • 9.4.5. Pricing of Pipeline Agents
  • 9.5. Physicians and Specialists Included in this Study
  • 9.6. Primary Research - Prescriber Survey
  • 9.7. About the Authors
    • 9.7.1. Author
    • 9.7.2. Global Head of Healthcare
  • 9.8. About GlobalData
  • 9.9. Disclaimer

List of Tables

  • Table 1: Symptoms of Atopic Dermatitis
  • Table 2: Treatment Guidelines for Atopic Dermatitis
  • Table 3: Most Prescribed Drugs for Atopic Dermatitis by Severity in the Global Markets, 2013
  • Table 4: Leading Treatments for Atopic Dermatitis, 2013
  • Table 5: Overall Unmet Needs in Atopic Dermatitis - Current Level of Attainment
  • Table 6: Clinical Unmet Needs in Atopic Dermatitis - Gap Analysis, 2013
  • Table 7: Late-Stage Atopic Dermatitis Pipeline, 2013
  • Table 8: Comparison of Therapeutic Classes in Development for Atopic Dermatitis, 2013
  • Table 9: Product Profile - Dupilumab
  • Table 10: Ongoing Clinical Trials of Dupilumab in Atopic Dermatitis Patients, as of September 2013
  • Table 11: Dupilumab SWOT Analysis, 2013
  • Table 12: Global Sales Forecasts ($m) for Dupilumab, 2012-2022
  • Table 13: Physicians Surveyed, By Country

List of Figures

  • Figure 1: Immunologic Pathway Involved in Healthy, Acute Atopic Dermatitis, and Chronic Atopic Dermatitis Skin
  • Figure 2: Flow Chart of the Diagnosis and Management of Atopic Dermatitis
  • Figure 3: Competitive Assessment of Late-Stage Pipeline Agents in Atopic Dermatitis, 2012-2022
Back to Top